Abby E. Odle

TL;DR: In this paper , the authors evaluated the ability of several B.1.529 isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters.

TL;DR: Nanosota-1C-Fc as discussed by the authors is a single-domain antibody that bound to the RBD of SARS-CoV-2 spike protein, blocking viral receptor angiotensin-converting enzyme 2 (ACE2).

TL;DR: In this paper, spike-specific antibody levels following vaccination were significantly higher than those seen in any non-vaccinated COVID-19 subjects tested to date at the facility, and spikespecific and neutralizing antibodies demonstrated dramatic increases following a single vaccination after COVID19 infection.

TL;DR: A novel series of single-domain antibodies, Nanosota-1, from a camelid nanobody phage display library is identified as a potentially effective and realistic solution to the COVID-19 pandemic.

TL;DR: Overall, these findings indicate that this RBD vaccine has broad-spectrum activity against multiple SARS-CoV-2 variants, as well as the potential to be effective and have improved efficacy against Omicron and other pandemic variants.